CapForce Inc. · OTC:CFOR
CapForce — Opgen — Merger or Acquisition (September 2019)
22 slides from CapForce's merger presentation, Sep 4, 2019
Slide 1: OpGen & Curetis Combining to build a stronger future
OpGen & Curetis Combining to build a stronger future September 04, 2019
Slide 2: Forward Looking Statements – OpGen, Inc.
FORWARD LOOKING STATEMENTS 2 ©2019 OpGen , Inc. & Curetis N.V. OpGen , Inc . This presentation includes statements relating to the proposed business combination between OpGen and Curetis . These statements and other statements regarding OpGen’s and the combined company’s future plans constitute "for
Slide 3: Forward Looking Statements – Curetis N.V.
FORWARD LOOKING STATEMENTS Curetis N . V . This document has been issued by Curetis N . V . (the “Company” and, together with its subsidiaries, the "Group") and does not constitute or form part of and should not be construed as any offer or invitation to sell or issue, or any solicitation of any off
Slide 4: Combining to Build a Stronger Future
COMBINING TO BUILD A STRONGER FUTURE Strategic Rationale • Establish a leading antimicrobial resistance (AMR) precision medicine business • Broad portfolio of high impact rapid diagnostics and best - in - class AMR bioinformatics • Leverage combined sales, distribution, bioinformatics and operating
Slide 5: Strategic Benefits
STRATEGIC BENEFITS Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global commercial channel capabil
Slide 6: Combined company addresses multiple high impact unmet clinical needs
U.S. and European market with high unmet medical need addressable through hospital - focused sales channels COMBINED COMPANY ADDRESSES MULTIPLE HIGH IMPACT UNMET CLINICAL NEEDS AND LARGE AVAILABLE MARKET OPPORTUNITIES The current portfolio and pipeline of cartridges target almost 10 million patients
Slide 7: Combined Company's Portfolio of Commercial Stage Products & Strategic Relationships
COMBINED COMPANY’S PORTFOLIO OF COMMERCIAL STAGE PRODUCTS & STRATEGIC RELATIONSHIPS Unyvero Platform & Tests Unyvero FDA - cleared platform and lower respiratory tract infection (LRT) test Acuitas Tests Acuitas tests in development and pending FDA clearance to improve antibiotic decision making Glob
Slide 8: Strategic Benefits
STRATEGIC BENEFITS ©2019 OpGen , Inc. & Curetis N.V. Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics
Slide 9: Molecular microbiology leadership through proprietary platforms and content
Molecular microbiology leadership through proprietary platforms and content SAMPLE - TO - ANSWER AND HIGH - THROUGHPUT TESTING CAPABILITIES * Unyvero A30 RQ Analyzer in development, latest design concept; final product may differ Striving for Molecular Microbiology Leadership MDx Platforms MDx Conte
Slide 10: Current and Near-Term U.S. Product Offerings
CURRENT AND NEAR - TERM U.S. PRODUCT OFFERINGS 10 ©2019 OpGen , Inc. & Curetis N.V. Unyvero Pneumonia (LRT) Acuitas AMR Gene Panel Description: ▪ Sample - to - answer multiplex PCR from native specimen in about 5 hours with ~2min hands - on time ▪ 36 Pathogen ID, 10 resistance genes Description: ▪ S
Slide 11: Unyvero A30 RQ Rapid Sample-to-Answer Testing Platform
UNYVERO A30 RQ RAPID SAMPLE - TO - ANSWER TESTING PLATFORM 11 ©2019 OpGen , Inc. & Curetis N.V. Key Design Features ▪ Fully integrated, closed, sample - to - answer MDx platform ▪ Universal real - time PCR technology for low - to mid - plex testing ▪ Flexible cartridge fluidics for numerous chemistr
Slide 12: Strategic Benefits
STRATEGIC BENEFITS ©2019 OpGen , Inc. & Curetis N.V. Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics
Slide 13: ARES Genetics & ARESdb
13 ARES GENETICS & ARESdb ©2019 OpGen , Inc. & Curetis N.V. Bioinformatics subsidiary with globally leading proprietary AI - powered knowledgebase for AMR informing PCR & NGS - based diagnostics Global ARESdb Database • Leading Knowledgebase on quantitative Antibiotic Resistance Markers building on
Slide 14: Acuitas Lighthouse: Diagnostics Data Management Platform
Cloud - based bioinformatics platform powers our ability to rapidly generate meaningful results that have the potential to change the landscape of clinical management and improve outcomes for patients ACUITAS LIGHTHOUSE®: DIAGNOSTICS DATA MANAGEMENT PLATFORM FOR ANTIBIOTIC RESISTANT PATHOGENS † Rapi
Slide 15: Strategic Benefits
STRATEGIC BENEFITS Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global commercial channel capabil
Slide 16: Commercial Strategy
OpGen and Curetis to realize synergies from a combined commercial effort COMMERCIAL STRATEGY Expanding global c ommercial r each though direct sales in U.S. and global distributors > Direct sales in the U.S. – combined team of 12 > European distribution through Menarini Diagnostics > China distribut
Slide 17: Pan-European Distribution by Menarini Diagnostics
Starting with 11 EU countries – option to expand relationship to further EMEA markets and additional product lines PAN - EUROPEAN DISTRIBUTION BY MENARINI DIAGNOSTICS Menarini Diagnostics Collaboration (Q1 - 2019) > Covers entire Unyvero A50 product line > Initial countries: BE, CH, DE ES, FR, IT, L
Slide 18: Strategic Benefits
STRATEGIC BENEFITS ©2019 OpGen , Inc. & Curetis N.V. Market leader positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics
Slide 19: Financial Considerations
FINANCIAL CONSIDERATIONS • Combined company positioned for strong growth profile and sustained value creation • FY2018 revenues of $1.6 million ( Curetis ) and $2.9 million ( OpGen ) • Estimated FY2019 combined revenue of $5 - 6 million • Estimated 2020 combined revenue of $10 - 15 million • Net los
Slide 20: Combined Company Senior Management Team
COMBINED COMPANY SENIOR MANAGEMENT TEAM Combined team has decades of experience in precision medicine, molecular diagnostics and capital markets Chairman of the Board: William Rhodes Chief Executive Officer: Oliver Schacht, Ph.D. Chief Financial Officer: Timothy C. Dec Board Members: William Rhodes
Slide 21: Transaction Timeline
• Both companies’ Boards of Directors have approved the implementation agreement • Both companies will seek approval from their respective shareholders in meetings to be scheduled for the fourth quarter of this year • Provided shareholders and debt holders for both OpGen and Curetis grant approval,
Slide 22: Thank You!
Thank You ! 22 ©2019 OpGen , Inc. & Curetis N.V.